Abstract
Purpose. Modulatory actions on morphine-induced effects, such as tolerance and withdrawal, have been noted for dynorphin A(1-13) [Dyn A(1-13)] and similar peptides. These are currently of limited therapeutic potential due to extensive metabolism by human metabolic enzymes resulting in a half-life of less than 1 min in human plasma. The purpose of this study was to identify stabilized dynorphin A (Dyn A) derivatives, to determine their metabolic routes in human plasma, and to assess whether the pharmacodynamic activity is retained.
Methods. The stability of peptides in human plasma was tested using in vitro metabolism studies with and without enzyme inhibitors. Identification of the generated metabolites was performed by mass spectrometry after high performance liquid chromatography (HPLC) separation. The in vivo activity of a stabilized dynorphin was tested by tail-flick assay in morphine-tolerant rats.
Results. Though amidation of the Dyn A(1-13) was able to stop the majority of C-terminal degradation, metabolism of Dyn A(1-10) amide continued by captopril sensitive enzymes, suggesting that Dyn A(1-13) amide is a better candidate for additional stabilization. Two Dyn A(1-13) amide derivatives further stabilized at the N-terminal end, [D-Tyr1]-Dyn A(1-13) amide and [N-Met-Tyr1]-Dyn A(1-13) amide, showed half-lives in plasma of 70 and 130 min, respectively. The most stable derivative [N-Met-Tyr1]-Dyn A(1-13) amide was tested successfully for retention of the pharmacological activity in modulating antinociceptive activity.
Conclusions. [N-Met-Tyr1]-Dyn A(1-13) amide showed significant stability and antinociceptive activity in the tail-flick test, thus pointing to the clinical potential of this derivative in the management of pain as well as its potential activity in suppressing opiate tolerance and withdrawal.
Similar content being viewed by others
REFERENCES
M. F. Powell, H. Grey, F. Gaeta, A. Sette, and S. Colon. Peptide stability in drug development: a comparison of peptide reactivity in different biological media. J. Pharm. Sci. 81:731–735 (1992).
M. D. Aceto, W. L. Dewey, J. K. Chang, and N. M. Lee. Dynorphin-( 1-13): effects in non-tolerant and morphine-dependent rhesus monkeys. Eur. J. Pharmacol. 83:139–142 (1982).
P. G. Green and N. M. Lee. Dynorphin A(1-13) attenuates withdrawal in morphine-dependent rats: Effect of route of administration. Eur. J. Pharmacol. 145:267–272 (1988).
A. E. Takemori, H. H. Loh, and N. M. Lee. Suppression by dynorphin A(1-13) of the expression of opiate withdrawal and tolerance in mice. Eur. J. Pharmacol. 221:223–226 (1992).
H. Wen and W. Ho. Suppression of withdrawal symptoms by dynorphin in heroin addicts. Eur. J. Pharmacol. 82:183–186 (1982).
L. P. Hooke and N. M. Lee. Dynorphin A modulates acute and chronic opioid effects. J. Pharmacol. Exp. Ther. 273:292–297 (1995).
F. C. Tulunay, M. F. Jen, J. K. Chang, H. H. Loh, and N. M. Lee. Possible regulatory role of dynorphin on morphine-and endorphin-dependent analgesia. J. Pharmacol. Exp. Ther. 219:296–298 (1981).
L. P. Hooke, L. He, and N. M. Lee. [Des-Tyr1] Dynorphin A-(2-17) has naloxone-insensitive antinociceptive effect in the writhing assay. J. Pharmacol. Exp. Ther. 273:802–807 (1995).
H. L. Wen, W. K. K. Ho, and P. Y. Wen. Comparison of the effectiveness of different opioid peptides in suppressing heroin withdrawal. Eur. J. Pharmacol. 100:155–162 (1984).
T. Uneklabh, P. Sintavanarong, V. Wessagowit, and L. Lunkanapiochonchut. Clinical effect of dynorphin on heroin addicts. J. Med. Assoc. Thai. 78:509–516 (1995).
S. Specker, W. Wananukul, D. Hatsukami, K. Nolin, L. Hooke, M. J. Kreek, and P. R. Pentel. Effects of dynorphin A(1-13) on opiate withdrawal in humans. Psychopharmacology (Berl.) 137: 326–332 (1998).
S. Muller and G. Hochhaus. Metabolism of dynorphin A(1-13) in human blood and plasma. Pharm. Res. 12:1165–1170 (1995).
P. L. Gambus, T. W. Schnider, C. F. Minto, E. J. Youngs, V. Billard, W. G. Brose, G. Hochhaus, and S. L. Shafer. Pharmacokinetics of intravenous dynorphin A(1-13) in opioid-naive and opioid-treated human volunteers. Clin. Pharmacol. Ther. 64:27–38 (1998).
F. Haviv, T. D. Fitzpatrick, R. E. Swenson, C. J. Nichols, N. A. Mort, E. N. Bush, G. Diaz, G. Bammert, A. Nguyen, and N. S. Rhutasel. Effect of N-methyl substitution of the peptide bonds in luteinizing hormone-releasing hormone agonists. J. Med. Chem. 36:363–369 (1993).
D. E. Benovitzand and A. F. Spatola. Enkephalin pseudopeptides: resistance to in vitro proteolytic degradation afforded by amide bond replacements extends to remote sites. Peptides 6: 257–261 (1985).
M. Hiramatsu, K. Inoue, A. Ambo, Y. Sasaki, and T. Kameyama. Long-lasting antinociceptive effects of a novel dynorphin analogue, Tyr-D-Ala-Phe-Leu-Arg _ (CH2NH) Arg-__2, in mice. Br. J. Pharmacol. 132:1948–1956 (2001).
J. P. Meyer, T. J. Gillespie, S. Hom, V. J. Hruby, and T. P. Davis. In vitro stability of some reduced peptide bond pseudopeptide analogues of dynorphin A. Peptides 16:1215–1219 (1995).
A. T. Hagler, D. J. Osguthorpe, P. Dauber-Osguthorpe, and J. C. Hempel. Dynamics and conformational energetics of a peptide hormone: vasopressin. Science 227:1309–1315 (1985).
T. S. Shippenberg, M. Funada, and C. G. Schutz. Dynorphin A(2-17) attenuates the unconditioned but not the conditioned effects of opiate withdrawal in the rat. Psychopharmacology (Berl.) 151:351–358 (2000).
R. C. Caudle and A. J. Mannes. Dynorphin: friend or foe? Pain 87:235–239 (2000).
S. Woo, J. Garzon, P. Sanchez-Blazquez, F. C. Tulunay, J. K. Chang, and H. H. Loh. Dynorphin(1-10)amide: a potent and selective analog of dynorphin(1-13). Life Sci. 31:1817–1820 (1982).
P. R. Pentel, W. Wananukul, L. P. Hooke, C. R. N. Jones, D. Hatsukami, W. R. Anderson, and N. M. Lee. Effects of high intravenous doses of dynorphin A(1-13) on tail flick latency and central nervous system histology in rats. Pharm. Biochem. Behav. 51:387–390 (1995).
F. E. Damourand and D. L. Smith. A method for determining loss of pain sensation. J. Pharmacol. Exp. Ther. 72:74–79 (1941).
A. B. Lohmann and F. L. Smith. Buprenorphine substitution ameliorates spontaneous withdrawal in fentanyl-dependent rat pups. Pediatr. Res. 49:50–55 (2001).
L. S. Harris and A. K. Pierson. Some narcotic antagonists in the benzomorphan series.J. Pharmacol. Exp. Ther. 143:141–148 (1964).
R. A. Skidgel and E. G. Erdos. Novel activity of human angiotensin I converting enzyme: release of the NH2-and COOHterminal tripeptides from the luteinizing hormone-releasing hormone. Proc. Natl. Acad. Sci. USA 82:1025–1029 (1985).
R. A. Skidgel, S. Engelbrecht, A. R. Johnson, and E. G. Erdos. Hydrolysis of substance p and neurotensin by converting enzyme and neutral endopeptidase. Peptides 5: 769–776 (1984).
R. A. Skidgel, D. K. Weerasinghe, and E. G. Erdos. Structure of human carboxypeptidase N (kininase I). Adv. Exp. Med. Biol. 247A:325–329 (1989).
H. S. Cheung, F. L. Wang, M. A. Ondetti, E. F. Sabo, and D. W. Cushman. Binding of peptide substrates and inhibitors of angiotensin-converting enzyme. Importance of the COOH-terminal dipeptide sequence. J. Biol. Chem. 255:401–407 (1980).
I. Lantzand and L. Terenius. High enkephalyl peptide degradation, due to angiotensin-converting enzyme-like activity in human CSF. FEBS Lett. 193:31–34 (1985).
A. M. Kawasaki, R. J. Knapp, A. Walton, W. S. Wire, T. Zalewska, H. I. Yamamura, F. Porreca, T. F. Burks, and V. J. Hruby. Syntheses, opioid binding affinities, and potencies of dynorphin A analogues substituted in positions, 1, 6, 7, 8 and 10. Int. J. Pept. Protein Res. 42:411–419 (1993).
A. E. Takemori, H. H. Loh, and N. M. Lee. Suppression by dynorphin A and [des-Tyr1]-dynorphin A peptides of the expression of opiate withdrawal and tolerance in morphine-dependent mice. J. Pharmacol. Exp. Ther. 266:121–124 (1993).
T. Nakazawa, Y. Furuya, T. Kaneko, K. Yamatsu, H. Yoshino, and S. Tachibana. Analgesia produced by E-2078, a systemically active dynorphin analog, in mice. J. Pharmacol. Exp. Ther. 252: 1247–1254 (1990).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Al-Fayoumi, S.I., Brugos, B., Arya, V. et al. Identification of Stabilized Dynorphin Derivatives for Suppressing Tolerance in Morphine-Dependent Rats. Pharm Res 21, 1450–1456 (2004). https://doi.org/10.1023/B:PHAM.0000036920.50291.5b
Issue Date:
DOI: https://doi.org/10.1023/B:PHAM.0000036920.50291.5b